Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Targeting the MMP-14/MMP-2/integrin αvβ3 axis with multispecific N-TIMP2-based antagonists for cancer therapy.

Yosef G, Arkadash V, Papo N.

J Biol Chem. 2018 Jul 9. pii: jbc.RA118.004406. doi: 10.1074/jbc.RA118.004406. [Epub ahead of print]

2.

A bi-specific inhibitor targeting IL-17A and MMP-9 reduces invasion and motility in MDA-MB-231 cells.

Koslawsky D, Zaretsky M, Alcalay R, Mazor O, Aharoni A, Papo N.

Oncotarget. 2018 Jun 19;9(47):28500-28513. doi: 10.18632/oncotarget.25526. eCollection 2018 Jun 19.

3.

A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.

Sananes A, Cohen I, Shahar A, Hockla A, De Vita E, Miller AK, Radisky ES, Papo N.

J Biol Chem. 2018 Jun 22. pii: jbc.RA117.000871. doi: 10.1074/jbc.RA117.000871. [Epub ahead of print]

4.

Tuning the molecular weight of polymeric amphiphiles as a tool to access micelles with a wide range of enzymatic degradation rates.

Slor G, Papo N, Hananel U, Amir RJ.

Chem Commun (Camb). 2018 Jun 19;54(50):6875-6878. doi: 10.1039/c8cc02415d.

PMID:
29774332
5.

Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases.

Cohen I, Naftaly S, Ben-Zeev E, Hockla A, Radisky ES, Papo N.

Biochem J. 2018 Apr 16;475(7):1335-1352. doi: 10.1042/BCJ20180070.

PMID:
29535275
6.

Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14.

Shirian J, Arkadash V, Cohen I, Sapir T, Radisky ES, Papo N, Shifman JM.

FEBS Lett. 2018 Apr;592(7):1122-1134. doi: 10.1002/1873-3468.13016. Epub 2018 Mar 12.

PMID:
29473954
7.

MIF inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: implications for familial ALS.

Shvil N, Banerjee V, Zoltsman G, Shani T, Kahn J, Abu-Hamad S, Papo N, Engel S, Bernhagen J, Israelson A.

Cell Death Dis. 2018 Jan 25;9(2):107. doi: 10.1038/s41419-017-0130-4.

8.

Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden.

Jendle J, Smith-Palmer J, Delbaere A, de Portu S, Papo N, Valentine W, Roze S.

Diabetes Ther. 2017 Oct;8(5):1015-1030. doi: 10.1007/s13300-017-0294-z. Epub 2017 Sep 4.

9.

A computational combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity.

Banerjee V, Oren O, Ben-Zeev E, Taube R, Engel S, Papo N.

J Biol Chem. 2017 Sep 22;292(38):15777-15788. doi: 10.1074/jbc.M117.789610. Epub 2017 Aug 2.

PMID:
28768772
10.

Engineering a monomeric variant of macrophage colony-stimulating factor (M-CSF) that antagonizes the c-FMS receptor.

Zur Y, Rosenfeld L, Bakhman A, Ilic S, Hayun H, Shahar A, Akabayov B, Kosloff M, Levaot N, Papo N.

Biochem J. 2017 Jul 20;474(15):2601-2617. doi: 10.1042/BCJ20170276.

PMID:
28655719
11.

Correction: Constitutive Association of Tie1 and Tie2 with Endothelial Integrins is Functionally Modulated by Angiopoietin-1 and Fibronectin.

Dalton AC, Shlamkovitch T, Papo N, Barton WA.

PLoS One. 2017 May 31;12(5):e0179059. doi: 10.1371/journal.pone.0179059. eCollection 2017.

12.

Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis.

Kapur S, Silverman AP, Ye AZ, Papo N, Jindal D, Blumenkranz MS, Cochran JR.

Bioeng Transl Med. 2017 Mar;2(1):81-91. doi: 10.1002/btm2.10051. Epub 2017 Feb 17.

13.

Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy.

Shlamkovich T, Aharon L, Barton WA, Papo N.

Oncotarget. 2017 May 16;8(20):33571-33585. doi: 10.18632/oncotarget.16827.

14.

Editorial overview: Engineering and design: New trends in designer proteins.

Shifman JM, Papo N.

Curr Opin Struct Biol. 2017 Aug;45:iv-vi. doi: 10.1016/j.sbi.2017.03.001. Epub 2017 Mar 15. No abstract available.

PMID:
28314629
15.

Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.

Arkadash V, Yosef G, Shirian J, Cohen I, Horev Y, Grossman M, Sagi I, Radisky ES, Shifman JM, Papo N.

J Biol Chem. 2017 Feb 24;292(8):3481-3495. doi: 10.1074/jbc.M116.756718. Epub 2017 Jan 13.

16.

Identifying Residues that Determine SCF Molecular-Level Interactions through a Combination of Experimental and In silico Analyses.

Rabinovich E, Heyne M, Bakhman A, Kosloff M, Shifman JM, Papo N.

J Mol Biol. 2017 Jan 6;429(1):97-114. doi: 10.1016/j.jmb.2016.11.018. Epub 2016 Nov 25.

PMID:
27890784
17.

An Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis.

Kayode O, Wang R, Pendlebury DF, Cohen I, Henin RD, Hockla A, Soares AS, Papo N, Caulfield TR, Radisky ES.

J Biol Chem. 2016 Dec 16;291(51):26304-26319. Epub 2016 Nov 3.

18.

Constitutive Association of Tie1 and Tie2 with Endothelial Integrins is Functionally Modulated by Angiopoietin-1 and Fibronectin.

Dalton AC, Shlamkovitch T, Papo N, Barton WA.

PLoS One. 2016 Oct 3;11(10):e0163732. doi: 10.1371/journal.pone.0163732. eCollection 2016. Erratum in: PLoS One. 2017 May 31;12 (5):e0179059.

19.

Superoxide Dismutase 1 (SOD1)-Derived Peptide Inhibits Amyloid Aggregation of Familial Amyotrophic Lateral Sclerosis SOD1 Mutants.

Banerjee V, Shani T, Katzman B, Vyazmensky M, Papo N, Israelson A, Engel S.

ACS Chem Neurosci. 2016 Nov 16;7(11):1595-1606. Epub 2016 Sep 2.

PMID:
27540759
20.

Protein Engineering by Combined Computational and In Vitro Evolution Approaches.

Rosenfeld L, Heyne M, Shifman JM, Papo N.

Trends Biochem Sci. 2016 May;41(5):421-433. doi: 10.1016/j.tibs.2016.03.002. Epub 2016 Apr 6. Review.

PMID:
27061494
21.

Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Cohen I, Kayode O, Hockla A, Sankaran B, Radisky DC, Radisky ES, Papo N.

Biochem J. 2016 May 15;473(10):1329-41. doi: 10.1042/BJ20151410. Epub 2016 Mar 8.

22.

Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France.

Roze S, Smith-Palmer J, Valentine W, Payet V, de Portu S, Papo N, Cucherat M, Hanaire H.

Diabetes Technol Ther. 2016 Feb;18(2):75-84. doi: 10.1089/dia.2015.0224. Epub 2015 Dec 8.

PMID:
26646072
23.

Combinatorial and Computational Approaches to Identify Interactions of Macrophage Colony-stimulating Factor (M-CSF) and Its Receptor c-FMS.

Rosenfeld L, Shirian J, Zur Y, Levaot N, Shifman JM, Papo N.

J Biol Chem. 2015 Oct 23;290(43):26180-93. doi: 10.1074/jbc.M115.671271. Epub 2015 Sep 10.

24.

Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.

Roze S, Saunders R, Brandt AS, de Portu S, Papo NL, Jendle J.

Diabet Med. 2015 May;32(5):618-26. doi: 10.1111/dme.12661. Epub 2015 Jan 6.

PMID:
25483869
25.

Heterogeneity in the systems of pediatric diabetes care across the European Union.

Cinek O, Sumník Z, de Beaufort C, Rurik I, Vazeou A, Madácsy L, Papo NL, Danne T; SWEET group.

Pediatr Diabetes. 2012 Sep;13 Suppl 16:5-14. doi: 10.1111/j.1399-5448.2012.00907.x.

PMID:
22931219
26.

Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.

Papo N, Silverman AP, Lahti JL, Cochran JR.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14067-72. doi: 10.1073/pnas.1016635108. Epub 2011 Aug 8.

27.

An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes.

Currie CJ, Poole CD, Papo NL.

Curr Med Res Opin. 2009 Oct;25(10):2389-400. doi: 10.1185/03007990903094452. Review.

PMID:
19650750
28.

Valuing condition-specific health states using simulation contact lenses.

Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK.

Value Health. 2009 Jul-Aug;12(5):793-9. doi: 10.1111/j.1524-4733.2009.00527.x.

29.

An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.

Taylor M, Scuffham PA, Chaplin S, Papo NL.

Value Health. 2009 Jun;12(4):459-65. doi: 10.1111/j.1524-4733.2008.00494.x. Epub 2009 Jan 14.

30.

Concerted release of substrate domains from GroEL by ATP is demonstrated with FRET.

Papo N, Kipnis Y, Haran G, Horovitz A.

J Mol Biol. 2008 Jul 18;380(4):717-25. doi: 10.1016/j.jmb.2008.05.021. Epub 2008 May 17.

31.

Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis.

Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA.

Br J Cancer. 2007 Aug 20;97(4):479-85. Epub 2007 Jul 24.

32.

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V.

Clin Breast Cancer. 2007 Jun;7(8):608-18.

PMID:
17592673
33.

Concerted ATP-induced allosteric transitions in GroEL facilitate release of protein substrate domains in an all-or-none manner.

Kipnis Y, Papo N, Haran G, Horovitz A.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3119-24. Epub 2007 Feb 21.

34.
35.

Effect of natural L- to D-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H.

Mangoni ML, Papo N, Saugar JM, Barra D, Shai Y, Simmaco M, Rivas L.

Biochemistry. 2006 Apr 4;45(13):4266-76.

PMID:
16566601
36.
37.

Utilizing ESEEM spectroscopy to locate the position of specific regions of membrane-active peptides within model membranes.

Carmieli R, Papo N, Zimmermann H, Potapov A, Shai Y, Goldfarb D.

Biophys J. 2006 Jan 15;90(2):492-505. Epub 2005 Oct 28.

38.

Mechanistic and functional studies of the interaction of a proline-rich antimicrobial peptide with mammalian cells.

Tomasinsig L, Skerlavaj B, Papo N, Giabbai B, Shai Y, Zanetti M.

J Biol Chem. 2006 Jan 6;281(1):383-91. Epub 2005 Oct 27.

39.

Host defense peptides as new weapons in cancer treatment.

Papo N, Shai Y.

Cell Mol Life Sci. 2005 Apr;62(7-8):784-90. Review.

PMID:
15868403
40.
41.
43.
44.
45.

Effects of the antimicrobial peptide temporin L on cell morphology, membrane permeability and viability of Escherichia coli.

Mangoni ML, Papo N, Barra D, Simmaco M, Bozzi A, Di Giulio A, Rinaldi AC.

Biochem J. 2004 Jun 15;380(Pt 3):859-65.

46.
47.

In vitro activity and mode of action of diastereomeric antimicrobial peptides against bacterial clinical isolates.

Pag U, Oedenkoven M, Papo N, Oren Z, Shai Y, Sahl HG.

J Antimicrob Chemother. 2004 Feb;53(2):230-9. Epub 2004 Jan 16.

PMID:
14729742
48.

Ranacyclins, a new family of short cyclic antimicrobial peptides: biological function, mode of action, and parameters involved in target specificity.

Mangoni ML, Papo N, Mignogna G, Andreu D, Shai Y, Barra D, Simmaco M.

Biochemistry. 2003 Dec 2;42(47):14023-35.

PMID:
14636071
49.
50.

A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice.

Papo N, Shahar M, Eisenbach L, Shai Y.

J Biol Chem. 2003 Jun 6;278(23):21018-23. Epub 2003 Mar 19.

Supplemental Content

Support Center